Letter to the editorOccurrence of B-cell lymphomas in patients with activated phosphoinositide 3-kinase δ syndrome
References (9)
- et al.
Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis
Cancer Cell
(2012) - et al.
A Mendelian predisposition to B-cell lymphoma caused by IL-10R deficiency
Blood
(2013) How I treat common variable immune deficiency
Blood
(2010)- et al.
Phosphoinositide 3-kinase delta gene mutation predisposes to respiratory infection and airway damage
Science
(2013)
Cited by (0)
S.K. is a Centre National de la Recherche Scientifique (CNRS) researcher. A.D., A.F., and S.K. are funded by Institut National de la Santé et de la Recherche Médicale. S.K. is supported by Fondation pour la Recherche Médicale (FRM: ING20130526624). A.D. is supported by the EUFP7 EUROPAD contract 201549, Association Contre Le Cancer, and the l'Agence Nationale de la Recherche (grant no. 2010-CSRD). A.F. is supported by the EUFP7 ERC PIDIMMUNE (grant no. 249816). S.N. is a Wellcome Trust Senior Research Fellow in Basic Biomedical Science (095198/Z/10/Z). S.N. is also supported by the European Research Council Starting grant 260477 and the EU FP7 collaborative grant 261441 (PEVNET project).
Disclosure of potential conflict of interest: J.-L. Casanova has received research support from the National Institutes of Health, the St Giles Foundation, Merck, BiogenIdec, and Pfizer and has had consultant arrangements with Pfizer, GlaxoSmithKline, NovImmune, BiogenIdec, Merck, and Sanofi. A. Fischer has received research support from INSERM and the European Union 7th Framework Programme ERC PIDIMMUNE. S. Nejentsev has received research support from the Wellcome Trust, the European Research Council, and the European Union 7th Framework Programme. A. Durandy has received research support from the European Union 7th Framework Programme EUROPAD, l'Agence Nationale de la Recherche (ANR), and l'Association de la Recherche contre le Cancer (ARC). The rest of the authors declare that they have no relevant conflicts of interest.